The patient with type 2 diabetes is hemodynamically and metabolically stable, despite treatment, the progression of chronic kidney disease proceeds. What other options do we have? A case report

Česká verzia

Authors: Zbynek Schroner
Authors place of work: Lekárska fakulta, Univerzita Pavla Jozefa Šafárika v Košiciach
Published in the journal: Diab Obez 2023; 23(45): 43-48
Category: Case studies

Summary

The case report describes a patient, which is hemodynamically and metabolically stable, despite treatment, the progression of CKD proceeds. Blocking of increased the mineralocorticoid receptor (MR) by selective, nonsteroidal MR antagonist – finerenone can slow down the progression of CKD, mediating by inflammation and fibrotic mechanisms, which current therapies do not solve, and by that, we can influence the third factor of progression of CKD and type 2 diabetes mellitus (T2DM). From 1st April 2023 in Slovakia finerenone reimbursed therapy is indicated to adult patients for the treatment of CKD with eGFR ≥ 25-< 60 ml/min/1,73 m² (≥ 0,42–< 1 ml/s/1,73 m²) and with albuminuria UACR ≥ 30–≤ 5 000 mg/g (≥ 3-≤ 500 mg/mmol) associated with T2DM, which are treated with a maximally tolerated dose of ACEi or ARB.

Keywords:

type 2 diabetes mellitus – chronic kidney disease – finerenone

Zdroje

1. Alicic RZ, Rooney MT, Tuttle KR et al. Diabetic Kidney Disease: Challenges, Progress, and Possibilities. Clin J Am Soc Nephrol 2017; 12(12): 2032–2045. Dostupné z DOI: <http://dx.doi.org/10.2215/CJN.11491116>.

2. Buonafine M, Bonnard B, Jaisse F et al. Mineralocorticoid receptor and cardiovascular disease. Am J Hypertension 2018; 31(11): 1165–1174. Dostupné z DOI: Dostupné z DOI: <http://dx.doi.org/10.1093/ajh/hpy120>.

3. Kolkhof P, Jaisser F, Kim SY et al. Steroidal and novel non-steroid mineralocorticoid receptor antagonists in heart failure and cardiorenal disease. Comparison at bench and bedside. Handb Exp Pharmacol 2017; 243: 271–305. Dostupné z DOI: <http://dx.doi.org/10.1007/164_2016_76>.

4. Bauersachs J, Jaisser F, Toto R. Mineralocorticoid receptor activation and mineralocorticoid receptor antagonist treatment in cardiac and renal disease. Hypertension 2015; 65(2): 257–263. Dostupné z DOI: <http://dx.doi.org/10.1161/HYPERTENSIONAHA.114.04488>.

5. Gomez-Sanchez E, Gomez-Sanchez CE. The multifaceted mineralocorticoid receptor. Compr Physiol 2014; 4(3): 965–994. Dostupné z DOI: <http://dx.doi.org/10.1002/cphy.c130044>.

6. Brown NJ. Contribution of aldosterone to cardiovascular and renal inflammation and fibrosis. Nat Rev Nephrol 2013; 9(8): 459–469. Dostupné z DOI: <http://dx.doi.org/10.1038/nrneph.2013.110>.

7. Biwer LA, Walllingford MC, Jaffe IZ. Vascular mineralocorticoid receptor: evolutionary mediator of wound healing turned harmful by our modern lifestyle. Am J Hypertension 2019; 32(2): 123–134. Dostupné z DOI: <http://dx.doi.org/10.1093/ajh/hpy158>.

8. Barrera-Chimal J, Girerd S, Jaisser F et al. Mineralocorticoid receptor antagonists and kidney diseases: pathophysiological basis. Kidney Int 2019; 96(2): 302–319. Dostupné z DOI: <http://dx.doi.org/10.1016/j.kint.2019.02.030>.

9. Pitt B, Kober L, Ponikowski P et al. Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94–8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial. Eur Heart J 2013; 34(31): 2453–2463. Dostupné z DOI: <http://dx.doi.org/10.1093/eurheartj/eht187>.

10. Bakris GL, Agarwal R, Chan JC et al. Effect of Finerenone on Albuminuria in Patients with Diabetic Nephropathy: A Randomized Clinical Trial. JAMA 2015; 314(9): 884–894. Dostupné z DOI: <http://dx.doi.org/10.1001/jama.2015.10081>.

11. Filippatos G, Anker SD, Böhm M et al. A randomized controlled study of finerenone vs eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease. Eur Heart J 2016; 37(27): 2105–2114. Dostupné z DOI: <http://dx.doi.org/10.1093/eurheartj/ehw132>.

12. Bakris GL, Agarwal R, Anker SD et al. Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes. N Engl J Med 2020; 383(23): 2219–2229. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa2025845>.

13. Pitt B, Filippatos G, Agarwal R et al. Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes. N Engl J Med 2021; 385(24): 2252–2263. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa2110956>.

14. Agarwal R, Filippatos G, Pitt B et al. Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis. Eur Heart J 2022; 43(6): 474–484. Dostupné z DOI: <http://dx.doi.org/10.1093/eurheartj/ehab777>. Erratum in Corrigendum to: Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis. [No authors listed]. Eur Heart J 2022; 43(20): 1989. Dostupné z DOI: <http://dx.doi.org/10.1093/eurheartj/ehab886>.

15. American Diabetes Association Professional Practice Committee. 11. Chronic Kidney Disease and Risk Management: Standards of Medical Care in Diabetes—2022. Diabetes Care 2022; 45(Suppl 1): S175–S184. Dostupné z DOI: <http://dx.doi.org/10.2337/dc22-S011>. Erratum in Erratum. 11. Chronic Kidney Disease and Risk Management: Standards of Medical Care in Diabetes-2022. Diabetes Care 2022; 45(Suppl 1): S175-S184. American Diabetes Association Professional Practice Committee. Diabetes Care 2022; 45(3): 758. Dostupné z DOI: <http://dx.doi.org/10.2337/dc22-er03>. Addendum. 11. Chronic Kidney Disease and Risk Management: Standards of Medical Care in Diabetes-2022. Diabetes Care 2022;45(Suppl. 1): S175-S184. American Diabetes Association Professional Practice Committee. Diabetes Care 2022; 45(9): 2182–2184. Dostupné z DOI: <http://dx.doi.org/10.2337/dc22-ad08a>.

16. Blonde L, Umpierrez GE, Reddy SS et al. American Association of Clinical Endocrinology. Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan – 2022 Update. Endocr Pract 2022; 28(10): 923–1049. Dostupné z DOI: <http://dx.doi.org/10.1016/j.eprac.2022.08.002>. Erratum in Corrigendum regarding American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan – 2022 Update.[No authors listed]. Endocr Pract 2023; 29(1): 80–81. Dostupné z DOI: <http://dx.doi.org/10.1016/j.eprac.2022.12.005>.

17. de Boer IH, Khunti K, Sadusky T et al. Diabetes Management in Chronic Kidney Disease: A Consensus Report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO). Diabetes Care 2022; 45(12): 3075–3090. Dostupné z DOI: <http://dx.doi.org/10.2337/dci22–0027>.

18. Rossing P, Caramori ML, Chan JC et al. Executive summary of the KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease: an update based on rapidly emerging new evidence. Kidney Int 2022; 102(5): 990–999. Dostupné z DOI: <http://dx.doi.org/10.1016/j.kint.2022.06.013>.

19. Kerendia 10 mg/Kerendia 20 mg. Súhrn charakteristických vlastností lieku. Dostupné z WWW: <https://www.ema.europa.eu/en/documents/product-information/kerendia-epar-product-information_sk.pdf>.

20. Zoznam kategorizovaných liekov 1. 4. 2023 – 30. 4. 2023. Dostupné z WWW: <https://www.health.gov.sk/Clanok?lieky202304>.